These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14508627)

  • 1. A simulation model at trabecular level to predict effects of antiresorptive treatment after menopause.
    van der Linden JC; Verhaar JA; Pols HA; Weinans H
    Calcif Tissue Int; 2003 Dec; 73(6):537-44. PubMed ID: 14508627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
    Boivin G; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
    Bonnick SL; Shulman L
    Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
    Seeman E
    Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanical consequences of bone loss in cancellous bone.
    van der Linden JC; Homminga J; Verhaar JA; Weinans H
    J Bone Miner Res; 2001 Mar; 16(3):457-65. PubMed ID: 11277263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bisphosphonates on matrix mineralization.
    Boivin G; Meunier PJ
    J Musculoskelet Neuronal Interact; 2002 Dec; 2(6):538-43. PubMed ID: 15758388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.
    Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P
    Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is bone mineral density predictive of fracture risk reduction?
    Cefalu CA
    Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE
    Bone; 2007 Jun; 40(6):1447-52. PubMed ID: 17045858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of high bone turnover on the biomechanical properties of the L3 vertebra in an ovine model of early stage osteoporosis.
    Kennedy OD; Brennan O; Mahony NJ; Rackard SM; O'Brien FJ; Taylor D; Lee CT
    Spine (Phila Pa 1976); 2008 Nov; 33(23):2518-23. PubMed ID: 18978592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
    Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
    Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of early menopause on bone mineral density and fractures.
    Gallagher JC
    Menopause; 2007; 14(3 Pt 2):567-71. PubMed ID: 17476146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of natural early menopause on bone mineral density.
    Francucci CM; Romagni P; Camilletti A; Fiscaletti P; Amoroso L; Cenci G; Morbidelli C; Boscaro M
    Maturitas; 2008 Apr; 59(4):323-8. PubMed ID: 18495388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
    Seeman E
    Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The basis for the post-parathyroidectomy increase in bone mass.
    Heaney RP
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N154-7. PubMed ID: 12412794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.